Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Barr Allegra approval

Executive Summary

Barr receives first ANDA approval for generic equivalent to Sanofi-Aventis'Allegra 60 mg capsules July 13. Barr maintains it is the first to file an ANDA for fexofenadine and is therefore entitled to a 180-day exclusivity period. Barr remains in litigation with Sanofi in New Jersey district court over five Allegra patents; the firm says the case may go to trial in early 2006. Barr was approved by FDA to market Allegra-D (fexofenadine/pseudoephedrine) generics in April, but has not yet launched the product (1"The Pink Sheet" April 18, 2005, In Brief)...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS046071

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel